1 | high | 78,757 |
2 | heightened | 483 |
3 | ultra-high | 109 |
4 | low-to-moderate | 77 |
5 | supraphysiological | 61 |
6 | moderate-to-high | 60 |
7 | supraphysiologic | 38 |
8 | ultrahigh | 37 |
9 | low-moderate | 34 |
10 | high-intermediate | 29 |
11 | moderate/high | 29 |
12 | moderate-high | 27 |
13 | above-average | 26 |
14 | low-intermediate | 23 |
15 | subinhibitory | 23 |
16 | low-medium | 19 |
17 | medium-high | 19 |
18 | subtoxic | 17 |
19 | low-to-medium | 13 |
20 | supranutritional | 13 |
21 | intermediate/high | 11 |
22 | subanaesthetic | 11 |
23 | near-zero | 10 |
24 | subnanomolar | 10 |
25 | intermediate-to-high | 9 |
26 | 100× | 8 |
27 | sub-nanomolar | 8 |
28 | 'personalised | 7 |
29 | low/medium | 7 |
30 | sero-protective | 7 |
31 | supra-physiological | 7 |
32 | high-cardiovascular | 6 |
33 | low-immunological | 6 |
34 | non-pathologic | 6 |
35 | target-site | 6 |
36 | ×40 | 6 |
37 | 200× | 5 |
38 | high/unclear | 5 |
39 | higher-than-normal | 5 |
40 | low-to-intermediate | 5 |
41 | moderate/low | 5 |
42 | high-chd | 4 |
43 | higher-than-average | 4 |
44 | mid-high | 4 |
45 | near-identical | 4 |
46 | preischaemic | 4 |
47 | superoptimal | 4 |
48 | 16x | 3 |
49 | intrapopulation | 3 |
50 | lower-than-average | 3 |
51 | sub-antimicrobial | 3 |
52 | sub-toxic | 3 |
53 | th11 | 3 |
54 | 2.0-mhz | 2 |
55 | 7-year-period | 2 |
56 | equi-iodine | 2 |
57 | femtogram | 2 |
58 | high-vascular | 2 |
59 | levitating | 2 |
60 | low-to-mid | 2 |
61 | low/middle | 2 |
62 | medium-level | 2 |
63 | p/5 | 2 |
64 | preanaesthesia | 2 |
65 | prebloom | 2 |
66 | precycle | 2 |
67 | problem-drinking | 2 |
68 | receptor/transporter | 2 |
69 | sub-cytotoxic | 2 |
70 | sub-insecticidal | 2 |
71 | submillisecond | 2 |
72 | 0.015-0.2 | 1 |
73 | 1.26-å | 1 |
74 | 1.3-a | 1 |
75 | 1.75å | 1 |
76 | 1.7å | 1 |
77 | 1.8-times-higher | 1 |
78 | 1.8-å | 1 |
79 | 1.86-å | 1 |
80 | 1.98-fold | 1 |
81 | 10.4-14.9 | 1 |
82 | 150x | 1 |
83 | 160× | 1 |
84 | 177-fold | 1 |
85 | 19-fold-higher | 1 |
86 | 2-times-higher | 1 |
87 | 2.1-a | 1 |
88 | 2.15-å | 1 |
89 | 2.9-å | 1 |
90 | 25‰ | 1 |
91 | 2750-fold | 1 |
92 | 2å | 1 |
93 | 3.00-d | 1 |
94 | 3.5-times-higher | 1 |
95 | 3.5× | 1 |
96 | 3.8-fold-increased | 1 |
97 | 3.95-fold | 1 |
98 | 30x | 1 |
99 | 4,559-m | 1 |
100 | 4-fold-increased | 1 |
101 | 4.031-fold | 1 |
102 | 4000x | 1 |
103 | 450-fold | 1 |
104 | 7-day-point | 1 |
105 | 7.17-fold | 1 |
106 | 73-fold-lower | 1 |
107 | 900x | 1 |
108 | acsm-recommended | 1 |
109 | asatisfactory | 1 |
110 | close-to-molecular | 1 |
111 | cycle-based | 1 |
112 | difficult-to-persuade | 1 |
113 | diiferent | 1 |
114 | fetus-specific | 1 |
115 | high-cvd | 1 |
116 | high-phase | 1 |
117 | high-statin | 1 |
118 | high-tissue | 1 |
119 | implantabutment | 1 |
120 | individually-adjusted | 1 |
121 | is-conduct | 1 |
122 | itmi | 1 |
123 | kikiros | 1 |
124 | least€97 | 1 |
125 | lectin-type | 1 |
126 | low-bpar | 1 |
127 | low-nm | 1 |
128 | mixed-literacy | 1 |
129 | mono-nucleosomal | 1 |
130 | nanomolecular | 1 |
131 | narratively.high | 1 |
132 | near-base | 1 |
133 | non-acceptable | 1 |
134 | non-negligent | 1 |
135 | non-psychoactive | 1 |
136 | non‑toxic | 1 |
137 | notch-sparing | 1 |
138 | paclitaxol | 1 |
139 | pharmacologically-achievable | 1 |
140 | pre-disclosure | 1 |
141 | rassi | 1 |
142 | readily-modifiable | 1 |
143 | reducingthe | 1 |
144 | sex-specified | 1 |
145 | single-base-pair | 1 |
146 | single-library | 1 |
147 | state-wise | 1 |
148 | still-existing | 1 |
149 | still-unpredictable | 1 |
150 | sub-coulomb | 1 |
151 | submicrolar | 1 |
152 | submyeloablative | 1 |
153 | sun-conscious | 1 |
154 | well-documenated | 1 |
155 | ∼2-3nm | 1 |
156 | ≤high | 1 |
157 | ≥1000-fold | 1 |
1 | 'personalised | 7 |
2 | 0.015-0.2 | 1 |
3 | 1.26-å | 1 |
4 | 1.3-a | 1 |
5 | 1.75å | 1 |
6 | 1.7å | 1 |
7 | 1.8-times-higher | 1 |
8 | 1.8-å | 1 |
9 | 1.86-å | 1 |
10 | 1.98-fold | 1 |
11 | 10.4-14.9 | 1 |
12 | 100× | 8 |
13 | 150x | 1 |
14 | 160× | 1 |
15 | 16x | 3 |
16 | 177-fold | 1 |
17 | 19-fold-higher | 1 |
18 | 2-times-higher | 1 |
19 | 2.0-mhz | 2 |
20 | 2.1-a | 1 |
21 | 2.15-å | 1 |
22 | 2.9-å | 1 |
23 | 200× | 5 |
24 | 25‰ | 1 |
25 | 2750-fold | 1 |
26 | 2å | 1 |
27 | 3.00-d | 1 |
28 | 3.5-times-higher | 1 |
29 | 3.5× | 1 |
30 | 3.8-fold-increased | 1 |
31 | 3.95-fold | 1 |
32 | 30x | 1 |
33 | 4,559-m | 1 |
34 | 4-fold-increased | 1 |
35 | 4.031-fold | 1 |
36 | 4000x | 1 |
37 | 450-fold | 1 |
38 | 7-day-point | 1 |
39 | 7-year-period | 2 |
40 | 7.17-fold | 1 |
41 | 73-fold-lower | 1 |
42 | 900x | 1 |
43 | above-average | 26 |
44 | acsm-recommended | 1 |
45 | asatisfactory | 1 |
46 | close-to-molecular | 1 |
47 | cycle-based | 1 |
48 | difficult-to-persuade | 1 |
49 | diiferent | 1 |
50 | equi-iodine | 2 |
51 | femtogram | 2 |
52 | fetus-specific | 1 |
53 | heightened | 483 |
54 | high | 78,757 |
55 | high-cardiovascular | 6 |
56 | high-chd | 4 |
57 | high-cvd | 1 |
58 | high-intermediate | 29 |
59 | high-phase | 1 |
60 | high-statin | 1 |
61 | high-tissue | 1 |
62 | high-vascular | 2 |
63 | high/unclear | 5 |
64 | higher-than-average | 4 |
65 | higher-than-normal | 5 |
66 | implantabutment | 1 |
67 | individually-adjusted | 1 |
68 | intermediate-to-high | 9 |
69 | intermediate/high | 11 |
70 | intrapopulation | 3 |
71 | is-conduct | 1 |
72 | itmi | 1 |
73 | kikiros | 1 |
74 | least€97 | 1 |
75 | lectin-type | 1 |
76 | levitating | 2 |
77 | low-bpar | 1 |
78 | low-immunological | 6 |
79 | low-intermediate | 23 |
80 | low-medium | 19 |
81 | low-moderate | 34 |
82 | low-nm | 1 |
83 | low-to-intermediate | 5 |
84 | low-to-medium | 13 |
85 | low-to-mid | 2 |
86 | low-to-moderate | 77 |
87 | low/medium | 7 |
88 | low/middle | 2 |
89 | lower-than-average | 3 |
90 | medium-high | 19 |
91 | medium-level | 2 |
92 | mid-high | 4 |
93 | mixed-literacy | 1 |
94 | moderate-high | 27 |
95 | moderate-to-high | 60 |
96 | moderate/high | 29 |
97 | moderate/low | 5 |
98 | mono-nucleosomal | 1 |
99 | nanomolecular | 1 |
100 | narratively.high | 1 |
101 | near-base | 1 |
102 | near-identical | 4 |
103 | near-zero | 10 |
104 | non-acceptable | 1 |
105 | non-negligent | 1 |
106 | non-pathologic | 6 |
107 | non-psychoactive | 1 |
108 | non‑toxic | 1 |
109 | notch-sparing | 1 |
110 | p/5 | 2 |
111 | paclitaxol | 1 |
112 | pharmacologically-achievable | 1 |
113 | pre-disclosure | 1 |
114 | preanaesthesia | 2 |
115 | prebloom | 2 |
116 | precycle | 2 |
117 | preischaemic | 4 |
118 | problem-drinking | 2 |
119 | rassi | 1 |
120 | readily-modifiable | 1 |
121 | receptor/transporter | 2 |
122 | reducingthe | 1 |
123 | sero-protective | 7 |
124 | sex-specified | 1 |
125 | single-base-pair | 1 |
126 | single-library | 1 |
127 | state-wise | 1 |
128 | still-existing | 1 |
129 | still-unpredictable | 1 |
130 | sub-antimicrobial | 3 |
131 | sub-coulomb | 1 |
132 | sub-cytotoxic | 2 |
133 | sub-insecticidal | 2 |
134 | sub-nanomolar | 8 |
135 | sub-toxic | 3 |
136 | subanaesthetic | 11 |
137 | subinhibitory | 23 |
138 | submicrolar | 1 |
139 | submillisecond | 2 |
140 | submyeloablative | 1 |
141 | subnanomolar | 10 |
142 | subtoxic | 17 |
143 | sun-conscious | 1 |
144 | superoptimal | 4 |
145 | supra-physiological | 7 |
146 | supranutritional | 13 |
147 | supraphysiologic | 38 |
148 | supraphysiological | 61 |
149 | target-site | 6 |
150 | th11 | 3 |
151 | ultra-high | 109 |
152 | ultrahigh | 37 |
153 | well-documenated | 1 |
154 | ×40 | 6 |
155 | ∼2-3nm | 1 |
156 | ≤high | 1 |
157 | ≥1000-fold | 1 |
1 | ×40 | 6 |
2 | th11 | 3 |
3 | 0.015-0.2 | 1 |
4 | p/5 | 2 |
5 | least€97 | 1 |
6 | 10.4-14.9 | 1 |
7 | 2.1-a | 1 |
8 | 1.3-a | 1 |
9 | preanaesthesia | 2 |
10 | sub-coulomb | 1 |
11 | fetus-specific | 1 |
12 | non-pathologic | 6 |
13 | supraphysiologic | 38 |
14 | preischaemic | 4 |
15 | subanaesthetic | 11 |
16 | sub-toxic | 3 |
17 | subtoxic | 17 |
18 | sub-cytotoxic | 2 |
19 | non‑toxic | 1 |
20 | 3.00-d | 1 |
21 | acsm-recommended | 1 |
22 | sex-specified | 1 |
23 | heightened | 483 |
24 | cycle-based | 1 |
25 | 4-fold-increased | 1 |
26 | 3.8-fold-increased | 1 |
27 | 'personalised | 7 |
28 | well-documenated | 1 |
29 | individually-adjusted | 1 |
30 | high-chd | 4 |
31 | low-to-mid | 2 |
32 | ≥1000-fold | 1 |
33 | 450-fold | 1 |
34 | 2750-fold | 1 |
35 | 4.031-fold | 1 |
36 | 3.95-fold | 1 |
37 | 7.17-fold | 1 |
38 | 177-fold | 1 |
39 | 1.98-fold | 1 |
40 | submillisecond | 2 |
41 | 7-year-period | 2 |
42 | high-cvd | 1 |
43 | difficult-to-persuade | 1 |
44 | above-average | 26 |
45 | higher-than-average | 4 |
46 | lower-than-average | 3 |
47 | reducingthe | 1 |
48 | readily-modifiable | 1 |
49 | still-unpredictable | 1 |
50 | non-acceptable | 1 |
51 | pharmacologically-achievable | 1 |
52 | precycle | 2 |
53 | low/middle | 2 |
54 | equi-iodine | 2 |
55 | lectin-type | 1 |
56 | pre-disclosure | 1 |
57 | near-base | 1 |
58 | high-phase | 1 |
59 | state-wise | 1 |
60 | high-intermediate | 29 |
61 | low-to-intermediate | 5 |
62 | low-intermediate | 23 |
63 | low-to-moderate | 77 |
64 | low-moderate | 34 |
65 | target-site | 6 |
66 | high-tissue | 1 |
67 | submyeloablative | 1 |
68 | non-psychoactive | 1 |
69 | sero-protective | 7 |
70 | problem-drinking | 2 |
71 | notch-sparing | 1 |
72 | levitating | 2 |
73 | still-existing | 1 |
74 | high | 78,757 |
75 | ultra-high | 109 |
76 | mid-high | 4 |
77 | moderate-high | 27 |
78 | medium-high | 19 |
79 | intermediate-to-high | 9 |
80 | moderate-to-high | 60 |
81 | narratively.high | 1 |
82 | intermediate/high | 11 |
83 | moderate/high | 29 |
84 | ultrahigh | 37 |
85 | ≤high | 1 |
86 | itmi | 1 |
87 | rassi | 1 |
88 | supra-physiological | 7 |
89 | supraphysiological | 61 |
90 | low-immunological | 6 |
91 | near-identical | 4 |
92 | sub-insecticidal | 2 |
93 | sub-antimicrobial | 3 |
94 | superoptimal | 4 |
95 | mono-nucleosomal | 1 |
96 | higher-than-normal | 5 |
97 | supranutritional | 13 |
98 | medium-level | 2 |
99 | paclitaxol | 1 |
100 | 4,559-m | 1 |
101 | femtogram | 2 |
102 | low-nm | 1 |
103 | ∼2-3nm | 1 |
104 | prebloom | 2 |
105 | low-to-medium | 13 |
106 | low-medium | 19 |
107 | low/medium | 7 |
108 | high-statin | 1 |
109 | intrapopulation | 3 |
110 | near-zero | 10 |
111 | high/unclear | 5 |
112 | sub-nanomolar | 8 |
113 | subnanomolar | 10 |
114 | submicrolar | 1 |
115 | close-to-molecular | 1 |
116 | nanomolecular | 1 |
117 | high-vascular | 2 |
118 | high-cardiovascular | 6 |
119 | low-bpar | 1 |
120 | 19-fold-higher | 1 |
121 | 2-times-higher | 1 |
122 | 3.5-times-higher | 1 |
123 | 1.8-times-higher | 1 |
124 | receptor/transporter | 2 |
125 | 73-fold-lower | 1 |
126 | single-base-pair | 1 |
127 | kikiros | 1 |
128 | sun-conscious | 1 |
129 | is-conduct | 1 |
130 | non-negligent | 1 |
131 | implantabutment | 1 |
132 | diiferent | 1 |
133 | 7-day-point | 1 |
134 | moderate/low | 5 |
135 | 4000x | 1 |
136 | 900x | 1 |
137 | 30x | 1 |
138 | 150x | 1 |
139 | 16x | 3 |
140 | mixed-literacy | 1 |
141 | single-library | 1 |
142 | asatisfactory | 1 |
143 | subinhibitory | 23 |
144 | 2.0-mhz | 2 |
145 | 100× | 8 |
146 | 200× | 5 |
147 | 160× | 1 |
148 | 3.5× | 1 |
149 | 2.15-å | 1 |
150 | 1.26-å | 1 |
151 | 1.86-å | 1 |
152 | 1.8-å | 1 |
153 | 2.9-å | 1 |
154 | 2å | 1 |
155 | 1.75å | 1 |
156 | 1.7å | 1 |
157 | 25‰ | 1 |